Novo Nordisk: Final approval for Tresiba and Ryzodeg in Europe - progressive launch expected

NEUTRAL, Fair Value DKK1000 (+1%)

News published on January Tuesday 22, 2013
Share on
Yesterday Novo-Nordisk received the final nod for the approval of its new-generation insulins Tresiba (long-acting) and Ryzodeg (mixed insulin) from the European Commission. It received a positive recommendation for both drugs in October 2012 from the CHMP.

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities